IDH1 and central nervous system cancer: Because available studies indicated that isocitrate dehydrogenase 1 (IDH1) mutants showed better prognosis compared to IDH-wildtype glioma patients at different WHO grades [25], therefore in the next step we analyzed proteasome activity depending on the mutation of the IDH1 gene.